CoChat

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

Open access
Elez, Elena, Ros, Javier, Fernández, Jose, Villacampa, Guillermo, Moreno-Cárdenas, Ana Belén, Arenillas, Carlota, Bernatowicz, Kinga, Comas, Raquel, Li, Shanshan, Kodack, David Philip, Fasani, Roberta, Garcia, Ariadna, Gonzalo-Ruiz, Javier, Piris-Gimenez, Alejandro, Nuciforo, Paolo, Kerr, Grainne, Intini, Rossana, Montagna, Aldo, Germani, Marco Maria, Randon, Giovanni, Vivancos, Ana, Smits, Ron, Graus, Diana, Perez-Lopez, Raquel, Cremolini, Chiara, Lonardi, Sara, Pietrantonio, Filippo, Dienstmann, Rodrigo, Tabernero, Josep, Toledo, Rodrigo A. · 2022 · Nature Medicine
Cited by 111

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic BRAFV600E colorectal cancer (mCRC BRAF-V600E). However, a large fraction of patients do not respond, underscoring the need to identify molecular determinants of treatment response. Using whole-exome sequencing in a discovery cohort of patients with mCRC BRAF-V600E treated with anti-BRAF/EGFR therapy, we found that inactivating mutations in RNF43, a negative regulator of WNT, predict improved response rates and survival outcomes in patients with microsatellite-stable (MSS) tumors. Analysis of an independent validation cohort confirmed the relevance of RNF43 mutations to predicting clinical benefit (72.7% versus 30.8%; P = 0.03), as well as longer progression-free survival (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.12–0.75; P = 0.01) and overall survival (HR, 0.26; 95% CI, 0.10–0.71; P = 0.008), in patients with MSS-RNF43mutated versus MSS-RNF43wild-type tumors. Microsatellite-instable tumors invariably carried a wild-type-like RNF43 genotype encoding p.G659fs and presented an intermediate response profile. We found no association of RNF43 mutations with patient outcomes in a control cohort of patients with MSS-mCRC BRAF-V600E tumors not exposed to anti-BRAF targeted therapies. Overall, our findings suggest a cross-talk between the MAPK and WNT pathways that may modulate the antitumor activity of anti-BRAF/EGFR therapy and uncover predictive biomarkers to optimize the clinical management of these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01976-z

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 111

Metadata

Authors
Elez, E., Ros, J., Fernández, J., Villacampa, G., Moreno-Cárdenas, A. B., Arenillas, C., Bernatowicz, K., Comas, R., Li, S., Kodack, D. P., Fasani, R., Garcia, A., Gonzalo-Ruiz, J., Piris-Gimenez, A., Nuciforo, P., Kerr, G., Intini, R., Montagna, A., Germani, M. M., Randon, G., Vivancos, A., Smits, R., Graus, D., Perez-Lopez, R., Cremolini, C., Lonardi, S., Pietrantonio, F., Dienstmann, R., Tabernero, J., & Toledo, R. A.
Venue
Nature Medicine
Published
2022-09-12
Volume
28
Issue
10
Pages
2162-2170
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4295513184
Cited by
111
References
21
FWCI
8.79
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer. https://app.cochat.ai/papers/10.1038/s41591-022-01976-z
The paper
Elez, E., Ros, J., Fernández, J., Villacampa, G., Moreno-Cárdenas, A. B., Arenillas, C., Bernatowicz, K., Comas, R., Li, S., Kodack, D. P., Fasani, R., Garcia, A., Gonzalo-Ruiz, J., Piris-Gimenez, A., Nuciforo, P., Kerr, G., Intini, R., Montagna, A., Germani, M. M., . . . Toledo, R. A. (2022). RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer. Nature Medicine. https://doi.org/10.1038/s41591-022-01976-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.